Evidence map›Paper›PMID 40659654›Full record

ArticleNature communications2025

Scaffold-hopping for molecular glues targeting the 14-3-3/ERα complex.

Markella Konstantinidou, Marios Zingiridis, Marloes A M Pennings, Michael Fragkiadakis, Johanna M Virta, Jezrael L Revalde, Emira J Visser, Christian Ottmann, Luc Brunsveld, Constantinos G Neochoritis and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Restoring the 14-3-3/CRAF regulatory interaction in Noonan syndrome using molecular glues.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Markella KonstantinidouDepartment of Pharmaceutical Chemistry and Small Molecule Discovery Centre (SMDC) University of California San Francisco (UCSF), San Francisco, CA, USA. markella.konstantinidou@ucsf.edu.ORCID http://orcid.org/0000-0001-5972-4140
Marios ZingiridisDepartment of Chemistry University of Crete Voutes, Heraklion, Greece.ORCID http://orcid.org/0009-0008-1150-2926
Marloes A M PenningsLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS) Eindhoven University of Technology, 5600 MB, Eindhoven, The Netherlands.ORCID http://orcid.org/0000-0002-3366-0238
Michael FragkiadakisDepartment of Chemistry University of Crete Voutes, Heraklion, Greece.
Johanna M VirtaDepartment of Pharmaceutical Chemistry and Small Molecule Discovery Centre (SMDC) University of California San Francisco (UCSF), San Francisco, CA, USA.
Jezrael L RevaldeDepartment of Pharmaceutical Chemistry and Small Molecule Discovery Centre (SMDC) University of California San Francisco (UCSF), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8794-6784
Emira J VisserLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS) Eindhoven University of Technology, 5600 MB, Eindhoven, The Netherlands.
Christian OttmannLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS) Eindhoven University of Technology, 5600 MB, Eindhoven, The Netherlands.ORCID http://orcid.org/0000-0001-7315-0315
Luc BrunsveldLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems (ICMS) Eindhoven University of Technology, 5600 MB, Eindhoven, The Netherlands.ORCID http://orcid.org/0000-0001-5675-511X
Constantinos G NeochoritisDepartment of Chemistry University of Crete Voutes, Heraklion, Greece. kneochor@uoc.gr.ORCID http://orcid.org/0000-0001-5098-5504
Michelle R ArkinDepartment of Pharmaceutical Chemistry and Small Molecule Discovery Centre (SMDC) University of California San Francisco (UCSF), San Francisco, CA, USA. michelle.arkin@ucsf.edu.ORCID http://orcid.org/0000-0002-9366-6770

Funding

Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
Systematic stabilization of specific protein-protein interactionsR01GM147696 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARKIN, MICHELLE · 2022 to 2025
$1.4M
Bruker Sierra SPR-24 ProS10OD030265 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARKIN, MICHELLE · 2021 to 2021
$304k
Netherlands Organisation for Scientific Research | Stichting voor de Technische Wetenschappen (Technology Foundation STW) Gravity program 024.001.035NIGMS NIH HHS R01 GM147696NIGMS NIH HHS T32 GM145460NIH HHS S10 OD030265U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM147696
6 · The paper itself

Abstract

Molecular glues, small molecules that bind cooperatively at a protein-protein interface, have emerged as powerful modalities for the modulation of protein-protein interactions (PPIs) and "undruggable" targets. The systematic identification of new chemical matter with a molecular glue mechanism of action remains a significant challenge in drug discovery. Here, we present a scaffold hopping approach, using as a starting point our previously developed molecular glues for the native 14-3-3/estrogen receptor alpha (ERα) complex. The novel, computationally designed scaffold is based on the Groebke-Blackburn-Bienaymé multi-component reaction (MCR), leading to drug-like analogs with multiple points of variation, thus enabling the rapid derivatization and optimization of the scaffold. Structure-activity relationships (SAR) are developed using orthogonal biophysical assays, such as intact mass spectrometry, TR-FRET and SPR. Rational structure-guided optimization is facilitated by multiple crystal structures of ternary complexes with the glues, 14-3-3 and phospho-peptides mimicking the highly disordered C-terminus of ERα. Cellular stabilization of 14-3-3/ERα for the most potent analogs is confirmed using a NanoBRET assay with full-length proteins in live cells. Our approach highlights the potential of MCR chemistry, combined with scaffold hopping, to drive the development and optimization of unprecedented molecular glue scaffolds.

Indexed as

14-3-3 ProteinsEstrogen Receptor alphaCrystallography, X-RayDrug DiscoveryHumansProtein BindingStructure-Activity Relationship14-3-3 ProteinsESR1 protein, humanEstrogen Receptor alpha

Identifiers

PMID40659654
PMCPMC12260087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.